Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Conditions

• Locally Advanced Paraganglioma
• Metastatic Adrenal Gland Pheochromocytoma
• Metastatic Paraganglioma
• Regional Adrenal Gland Pheochromocytoma
• Unresectable Adrenal Gland Pheochromocytoma
• Unresectable Paraganglioma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cabozantinib S-malate — DRUG
  Given PO
• Laboratory Biomarker Analysis — OTHER
  Correlative studies
• Questionnaire Administration — OTHER
  Ancillary studies

Study Details

This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.

Key Dates

Start date

Feb 17, 2015

Status verified

Jul 2025

Primary completion

Nov 12, 2024

Completion

Nov 12, 2024

Study Design

Enrollment

21 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (cabozantinib s-malate)
  Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Objective Response Rate [ Time Frame: 6 months ]

Locations (1)

Find similar trials in Houston, TX